Leica Biosystems is a global leader in anatomic pathology solutions with a rich history spanning more than 150 years, originating from a family optics business founded in 1849 in Wetzlar, Germany. The company is part of Danaher Corporation since 2006 and specializes in comprehensive cancer diagnostics workflows from biopsy to diagnosis.
Leica Biosystems offers a wide-ranging portfolio of products and services that cover every step in the pathology process, including sample preparation, staining, imaging, and reporting. This full workflow ownership enables them to seamlessly integrate and enhance the efficiency and accuracy of cancer diagnoses.
The company is driven by innovation and invests heavily in research and development, aiming to empower clinicians with tools that provide highly confident diagnoses swiftly, often targeting within 24 hours from biopsy. Their commitment to innovation is supported by a substantial patent portfolio and customer insights.
Leica Biosystems envisions a future where comprehensive clinical insights enrich cancer diagnosis and bring reassurance to patients worldwide. Presently, the company facilitates over 1.6 million cancer diagnoses each week, significantly impacting global healthcare by transforming patient anxiety into diagnostic clarity.
Their core mission statement, “Advancing Cancer Diagnostics, Improving Lives,” reflects the company culture and strategic focus on improving outcomes for cancer patients through advanced pathology solutions and digital pathology technologies.